Introduction {#s1}
============

Overestimation of threatening situations is one major aspect for the development of pathological fear memories ([@CIT0028]). Effective treatment of anxiety disorders depends on understanding how fear is memorized and regulated ([@CIT0022]). The most effective treatment used to address pathological fear is behavioral therapy based on exposure-based methods. In this form of therapy, threatening stimuli are presented repeatedly to the patients until the fear response is reduced or diminished ([@CIT0036]). Much of our understanding emerges from the traditional Pavlovian fear-conditioning paradigm where a neutral stimulus (conditioned stimulus \[CS\]) is coupled with an unpleasant stimulus (unconditioned stimulus \[UCS\]). After a few CS-UCS couplings, the CS becomes effective in eliciting a fear-based conditioned response (CR) and thereby establishes a fear memory. The defensive response to the reinforced CS can be reduced or diminished through extinction training (i.e. repeated presentation of non-reinforced CS), thereby showing that the CS no longer predicts a threat ([@CIT0036]; [@CIT0022]).

Nevertheless, a return of fear has been reported even after successful extinction training ([@CIT0043]). Hence, much effort has been put into the development of effective treatment to prevent fear from returning. The efficacy of using pharmacological treatment to prevent pathological memories from returning has been well established, yet its effect in humans remains unpredictable and unverified ([@CIT0044]). Recent studies in both humans ([@CIT0046]; [@CIT0001]; [@CIT0039]) as well as animal models ([@CIT0034]) show that a single brief exposure of a non-reinforced CS used for memory reactivation just before extinction training can attenuate pathological memories. This attenuation could be due to the fact that memory becomes labile upon reactivation and undergoes reconsolidation. Nevertheless, some studies also failed to affect reconsolidation ([@CIT0010]; [@CIT0018]; [@CIT0023]; [@CIT0056]). An important issue previously not addressed in detail is whether the failure to update old information (i.e. memory reconsolidation) might result from inter-individual differences (e.g. conferred by genetic variation as reported earlier; [@CIT0002]). The maintenance of reactivated fear memories (i.e. human fear reconsolidation) might be suppressed by certain allelic differences and enhanced by others. For example, individuals with the short-allele of the serotonin-transporter (*5-HTTLPR*) and *val/val* homozygotes of the functional *val158met* polymorphism of the *catechol O-methyltransferase* (*COMT*) exhibited the reacquisition of fear within the reconsolidation window ([@CIT0002]).

In addition to *5-HTTLPR* and the *COMT* polymorphism, other polymorphisms have been shown to influence processes of learning and memory. For example, *Met*-allele carriers of brain-derived neurotrophic factor polymorhism (*BDNF val66met*) have been associated with alterations of hippocampal plasticity and weak episodic memory ([@CIT0016]). In addition, the *met*-allele has been associated with the attenuation of hippocampal activation during encoding and retrieval of a declarative memory task ([@CIT0020]), which suggests a role in memory processes ([@CIT0007]). Moreover, a recent animal study ([@CIT0042]) demonstrated a putative role of BDNF in the reconsolidation of extinction memory. It was shown that the direct infusion of BDNF into the hippocampus impaired reconsolidation of extinction memory both 6 hours or immediately after reactivation of learned fear in rats. This highlights an important role of BDNF in the maintenance of reactivated fear memories, and hence in the fear reconsolidation update mechanism as well.

Furthermore, the *BDNF val66met* polymorphism is closely associated with memory dysfunction ([@CIT0033]). The *met*-allele is associated with lower levels of activity-dependent secretion and distribution of BDNF protein in neurons ([@CIT0016]) and with lower activity of BDNF secretion in general ([@CIT0045]), which leads to an impairment in learning and memory processes ([@CIT0025]). In accordance with the neurobiological effects of BDNF, the *BDNF val66met* polymorphism has been shown to modulate hippocampus-related memory processes ([@CIT0011]). For example, animal studies have consistently affirmed the relevance of BDNF/neutrophic tyrosine kinase receptor B (TrkB) signalling in learning and memory processes ([@CIT0032]; [@CIT0025]). In humans, *BDNF met*-allele carriers display differences in hippocampal morphology, which leads to selective memory dysfunction ([@CIT0035]).

Prior investigations ([@CIT0016]; [@CIT0013]) have shown that increased expression and secretion of BDNF protein is strongly associated with learning and memory. This, it is possible that the *BDNF* polymorphism may modulate reactivated fear memories targeting reconsolidation mechanism. The involvement of BDNF in memory stabilization ([@CIT0007]), resemebles the reconsolidation mechanism, which acts to stabilizes a reactivated memory ([@CIT0037]; [@CIT0038]). Such an interaction would suggest a failure to target reconsolidation and could be associated with inter-individual differences. Alternatively, the combined effect of reactivated memory and allelic differences might moderate the reconsolidation mechanism.

Therefore, we tested a large sample of healthy volunteers to investigate whether a functional *BDNF val66met* polymorphism affects the return of fear using reconsolidation update mechanisms (by applying reminder presentation followed by extinction training). We hypothesized that *BDNF met*-allele carriers would show less persistence of fear memory.

Materials and Method {#s2}
====================

Participants {#s3}
------------

One hundred and forty-three healthy participants of Caucasian descent were recruited via online advertisements to participate in the present study. The study was described briefly to the interested participants, with the information that the study was conducted on 3 consecutive days and included collection of a blood sample; 24 Euros were given as compensation. Participants were eligible for inclusion if they met the following criteria: (i) age 18--40 years; and (ii) German native speaker. Participants were excluded from the trial if they met the following criteria: (i) any neurological or psychiatric illnesses; (ii) pregnancy; or (iii) students with psychology as major. Information about these criteria was obtained through questionnaires (see below). Participants were randomly assigned into two groups: the reminder and non-reminder groups. After data analysis (see below), five participants were excluded due to artefacts (i.e. origin of response to stimuli before a baseline in more than eight numbers of trials resulting in less than three artefact-free trials for each condition) and 26 participants were excluded because they did not show a conditioned response (that means: conditioned stimuli CS+ \> CS- during acquisition and also CS+ during acquisition \> CS+ during habituation). Four participants did not volunteer to participate in extinction training (24 hours later: day 2). Sixteen participants either did not donate blood or their blood samples could not be genotyped correctly, and one participant was dropped due to data corruption. The demographical data of the remaining 91 participants is shown in [Table 1](#T1){ref-type="table"}. According to recent literature ([@CIT0019]; [@CIT0026]; [@CIT0053]), participants were placed into two groups: *met*-allele carriers (*met66met* and *val66met*) and *val*-allele homozygotes (*val66val*). Genotype groups did not differ with respect to sex and age (see [Table 1](#T1){ref-type="table"}). The study was in accordance with the declaration of Helsinki in its latest version from 2008 and has been approved by the local ethical board. All participants gave their written informed consent.

###### 

Descriptive Data of Final Sample by Reminder, Sex, and *BDNF* Genotype Subgroups

  Experimental Group   Gender      Met66Met/ Val66Met   Val66Val    X^2^   *p*-Value   d'
  -------------------- ----------- -------------------- ----------- ------ ----------- ------
  Reminder             Females     14.6 (6)             29.2 (12)   .01    .92         -.02
  Males                19.5 (8)    36.5 (15)                                           
  Non-reminder         Females     24.0 (12)            24.0 (12)   .29    .59         .08
  Males                22.0 (11)   30.0 (15)                                           

Results are expressed as percentage with the number of subjects in brackets. n = 91

Psychometric Characterization {#s4}
-----------------------------

To characterize the participants of this study and to ensure that the different genotype groups did not differ with respect to relevant anxiety traits, the Anxiety Sensitivity Index (ASI 3; [@CIT0052]), the Fear Questionnaire (FQ; [@CIT0029]), the Positive And Negative Affect Scale (PANAS; [@CIT0055]), the Penn State Worry Questionnaire (PSWQ; [@CIT0031]), the Spielberg State-Trait Anxiety Inventory (STAI-T; [@CIT0051]), the Allgemeine Depressions Skala (a screening instrument for depressive symptoms, in its short version; ADS-k; [@CIT0027]), and the Behavioral Inhibition/Behavioral Approach System Scale (BIS/BAS scale) [@CIT0009]) were completed by each participant. In [Table 2](#T2){ref-type="table"}, psychometric characteristics are given for the two experimental groups (reminder vs non-reminder) and the two *BDNF* genotype groups (*met66met* and *val66met* vs *val66val*).

###### 

Univariate Analysis of Variance Results

  ---------------------------------------------------------------------------------------------------
                    Reminder     Non-Reminder   F-Values                                     
  ----------------- ------------ -------------- ------------ ------------ ------- ---------- --------
  FQ                1.47 (.82)   1.27 (.71)     1.21 (.71)   1.26 (.77)   0.72    .22        .64

  PANAS~1~          2.27 (.28)   2.41 (.41)     2.17 (.38)   2.37 (.42)   .70     4.06\*     .10

  PANAS~2~          2.62 (.38)   2.51 (.39)     2.36 (.42)   2.60 (.36)   .90     .61        4.10\*

  PSWQ              2.30 (.41)   2.35 (.38)     2.11 (.47)   2.19 (.42)   3.65+   0.60       .03

  STAI              1.00 (.47)   .99 (.50)      .72 (.59)    .90 (.48)    2.68    .62        .74

  ADSk              .75 (.25)    .74 (.31)      .68 (.31)    .73 (.30)    0.08    3.45+      .00

  BIS               2.25 (.27)   2.09 (.30)     2.27 (.34)   2.05 (.35)   .01     7.33\*\*   .26

  BAS drive         2.01 (.56)   2.05 (.47)     1.86 (.45)   1.86 (.58)   2.38    .02        .01

  BAS fun\          1.98 (.57)   1.94 (.45)     1.84 (.45)   1.73 (.42)   2.87+   .67        .12
  seeking                                                                                    

  BAS reward resp   1.70 (.44)   1.60 (.40)     1.59 (.32)   1.42 (.31)   3.34+   2.94+      .19

  ASI 3             1.00 (.47)   .99 (.49)      .73 (.59)    .91 (.48)    2.68    .62        .74
  ---------------------------------------------------------------------------------------------------

df = 89, displayed are the mean (with the standard deviation in brackets) for the four groups.

ADSk, Allgemeine Depressions Skala; ASI 3, Anxiety Sensitivity Index; B, main effects *BDNF* genotype group effects; BIS, Behavioral Inhibition System; BAS, Behavioral Approach System; BDNF, brain derived neurotrophic factor; FQ, Fear Questionnaire; PANAS, Positive and Negative Affect Scale; PANAS~1~, positive affect; and PANAS~2~, negative affect; PSWQ, Penn State Worry Questionnaire; R = main effects reminder group; R\*B, interaction effects of R and B; STAI, Spielberger State-Trait Anxiety Inventory.

\+*p* \< 0.10, \**p* \<0.05, \*\**p* \<0.01).

The main effect for BIS can be explained by higher values in *met*-allele carriers compared to *val66val* homozygotes. The main effect for PANAS1 (positive affect) can be explained by higher values in *val66val* homozygotes. The significant interaction effect of *BDNF* x group for PANAS2 (negative affect) can be explained by a lower negative affect in the no-reminder group for *met*-allele carriers compared to *val66val* homozygotes (t\[48\] = -2.2, *p* \< 0.05). However, none of these main or interaction effects survive a strict Bonferroni correction with *p* \< 0.004.

SCR Recording and Analyses {#s5}
--------------------------

Skin conductance responses (SCRs) were recorded from the volar surfaces on medial phalanges of the participants' non-dominant palm ([@CIT0014]) as a means to measure the psychophysiological effects of fear learning. SCRs were recorded with the help of a V-Amp 16 (Brain Products GmbH), a 16-channel direct current amplifier system using the BrainVision Recorder Software (V-Amp Edition 1.10, Brain Products GmbH), at a sampling rate of 1000 Hz. All data was filtered with a 50 Hz notch filter during recording. SCRs were recorded using two Ag/AgCl electrodes (diameter = 13mm) filled with non-hydrating gel.

SCRs data was filtered offline with a 1 Hz low pass filter and segmented into different phases (e.g. habituation, acquisition, extinction, and re-extinction) as well as single CS+ and CS- trials. Thereafter, each segment was baseline corrected 1000ms prior to the onset of the stimuli and characterized by taking the maximum of the SCR deflection in the 1--4.5 second interval after stimulus onset, consistent with the previous study ([@CIT0004]). All SCRs scores were square root transformed to normalize distributions and were then range-corrected ([@CIT0054]; [@CIT0046]) by using the maximum (unconditioned) deflection (peak between 4.5 and 7.5s during fear acquisition) elicited by the UCS as the maximum range for each individual.

Procedure {#s6}
---------

The present study was conducted on 3 consecutive days, 20 hours to 26 hours apart. The first session (day 1) consisted of a habituation and acquisition period, in which participants learned the association of conditioned (CS) and unconditioned stimuli (UCS). During these two phases, blue and yellow colored squares (presented at a 16degree visual angle) were presented to the participants in a randomized order on a PC monitor for 4s with an inter-stimulus interval of 10--12s and counterbalanced as CS+ and CS- to each participant, so both squares were equally often selected as CS+ and CS-. Stimuli were presented in a pseudo-randomized order (i.e. not more than two consecutive trials of the same CS in a row were repeated) using Presentation Version 13.0 software (Neurobehavioral Systems, Inc.).

During the habituation phase, eight trials of each square (i.e. blue and yellow) were presented to reach a stable response to the stimuli. In the acquisition phase, 16 trials of squares of each color were presented. Along with one of the colored squares, a woman's scream (code number 276 adapted from the International Affective Digital Sounds for 2s of 102 db loudness) was presented 2s after CS+ onset, while the other square served as CS- (color was randomized between both conditions). Sixteen CS+ and CS- were presented, with an 80% reinforcement rate (i.e. 80% CS+ trials were paired with UCS).

During the second day (day 2), participants of the reminder group first underwent re-activation, which was followed by extinction training (16 CS+, 16 CS-). In the re-activation phase, a single presentation of the CS+ for 4s without the UCS served as a reminder trial. The experimental group received the reminder trial 10 minutes before extinction training. In contrast, the reminder trial was never presented in the control group, but extinction training also started after a 10 minutes break. Extinction training consisted of repeated presentation of CS+ and CS- in absence of the UCS.

A day later (day 3), both groups (control and experimental group) underwent extinction training (16 CS+, 16 CS-) for a second time in order to trace the spontaneous recovery of previously learned fear memory contents. On all days, headphones and skin conductance electrodes were connected to all of the participants and the SCR were recorded from the start until the end ([@CIT0004]).

Genotyping {#s7}
----------

Participants were genotyped for the functional *BDNF val66met* polymorphism (rs6265) according to previously published protocols ([@CIT0021]). Genotyping was performed by standard polymerase chain reaction applying the following primers, forward (5′-AAA GAA GCA AAC ATC CGA GGA CAA G) and reverse (5′-ATT CCT CCA GCA GAA AGA GAA GAG G). The distribution of genotypes was in Hardy-Weinberg equilibrium (G/G: 54 \[59.3%\], G/A: 31 \[34.1%\], A/A: 6 \[6.6 %\], χ^2^ = 0.29, *p* = 0.87). The allele distribution did not differ between both experimental groups (X^2^ =1.31; n.s.; see [Table 3](#T3){ref-type="table"}).

###### 

Percentage and Statistics of the Participants' Distribution Over *BDNF* Polymorphisms and Experimental Group

  Experimental group   Met66Met   Val66Met    Val66Val    X^2^   *p*-Value
  -------------------- ---------- ----------- ----------- ------ -----------
  Reminder             7.3 (3)    26.8 (11)   65.9 (27)   1.31   .25
  Non-reminder         6.0 (3)    40.0 (20)   54.0 (27)          

Results are expressed as percentage with the number of subjects in brackets. BDNF, brain derived neurotrophic factor.

Subjective Ratings {#s8}
------------------

In the current study, individual fear learning was also assessed using ratings of subjective experience. As reported earlier, subjective experience is particularly sensitive to emotional valence and arousal. Moreover, in a fear conditioning paradigm, physiological recordings (e.g. skin conductance response) are sensitive to emotional arousal ([@CIT0006]). Subjective CS+ and CS- ratings were assessed at different experimental phases using self-assessment manikins ([@CIT0008]) for both valence and arousal. Subjects were asked to report whether the blue/yellow squares were perceived as pleasant or unpleasant and whether they induced arousal or calmness on a 9-point Likert scale. On the ratings of valence and arousal, 1 was labelled very unpleasant/calm, and 9 was labelled very pleasant/arousing, respectively. In addition, all participants were verbally questioned after each experimental phase about the perceived likelihood that the UCS occurred during the presentation of each CS+ (contingency awareness), although this response was not recorded.

Statistical Analysis {#s9}
--------------------

Preprocessing and statistical analysis were performed using Vision Analyzer 2.0 (Brain Products GmbH) and SPSS version 21.0 (IBM SPSS Statistics). Demographic data such as gender (male, female) and genotype (*met66met*/*met66val*, *val66val*) were compared between groups (reminder, no-reminder) by using a chi-square test (see [Tables 1](#T1){ref-type="table"} and [3](#T3){ref-type="table"}). Psychometric data (arousal, valence, ASI, FQ, PANAS, PSWQ, STAI-T, ADS-k, and BIS-BAS scores) were analyzed by using the univariate analysis of variance (see [Table 2](#T2){ref-type="table"}). The ratings for the arousal and valence are reported in the Supplementary Material (see [Supplementary Table 1](http://ijnp.oxfordjournals.org/lookup/suppl/doi:10.1093/ijnp/pyv137/-/DC1)).

To evaluate fear conditioning, extinction, and spontaneous recovery, differential SCRs values (CS+ minus CS-) were calculated for each experimental phase (acquisition, extinction and re-extinction; [@CIT0002]). Furthermore, the two trials of both CS+ and CS- were averaged across the total number of trials (i.e. 16 trials in each). Each single trial block is comprised of two trials. Hence, in total we conducated four trial blocks during habituation and eight trial blocks each for CS+ and CS- during acquisition, extinction, and re-extinction. For the statistical analysis, the first four trial blocks (trials 1--8) were during acquisition, the last two trial blocks (trials 13--16) were during extinction, and the first trial block (trials 1--2) was taken into consideration and statistically evaluated using repeated measures analysis of variance (ANOVA) with phase mean as the within-subject factors and group (reminder, no-reminder) as the between-subject factor. To test the spontaneous recovery, the last two trial blocks of extinction and the first trial block of re-extinction were considered. Significant interaction effects were further elucidated by post-hoc *t*-tests at a significance level of *p* \< 0.05 (two-tailed). Non-sphericity was considered by applying the Greenhouse-Geisser correction.

Results {#s10}
=======

Effect of Reactivation on Reconsolidation {#s11}
-----------------------------------------

The reminder group was given a single brief exposure of non-reinforced CS+ (without presentation of the UCS). The effect of reactivation was evaluated by assessing whether there was an increase in ∆ SCR (CS+ minus CS-) from the end of extinction (last two trials of day 2) to re-extinction (first two trials of day 3). This analysis revealed no effect of time (F \[1, 89\] = 0.18; *p* = 0.67), group (F\[1,89\] = 2.60; *p* = 0.11) or time x group (F \[1, 89\] = 0.30; *p* = 0.59), suggesting that reactivation of learned content did not affect memory reconsolidation.

Effect of Genotype on Reconsolidation {#s12}
-------------------------------------

The effect of the reminder in relation to the *BDNF* genotype on fear reconsolidation ([Figures 1B](#F1){ref-type="fig"} and 2A and B) was assessed using a three-way ANOVA with a 2 x 2 x 2 (group x genotype x time) design, for ∆ SCRs (CS+ minus CS-) during extinction (again the last two trials of day 2) and re-extinction (first two trials of day 3). This showed a significant interaction effect of time x group x genotype (F \[1, 87\] = 11.89; *p* \< 0.001). No significant main effect of time (F\[1,87\] = 0; *p* = 0.99), group (F\[1,87\] = 2.3; *p* = 0.13), genotype (F\[1,87\] = 1.66; *p* = 0.20), or further interaction effects were found (group x genotype, F\[1,87\] = 1.12, *p* = 0.29; group x time, F\[1,87\] = 1.56, *p* = 0.22; genotype x time, F\[1,87\] = 0.003, *p* = 0.96). Post hoc tests revealed a tendency for reduced amplitudes during re-extinction for the reminder group (t\[13\] = 1.83; *p* \< 0.10) and increased amplitudes during re-extinction for the no-reminder group (t\[22\] = -2.88; *p* \< 0.01), but only for *met* allele carriers. For *non-met* allele carriers, no significant differences between groups were found. Comparing the reminder group with the no-reminder group revealed significant higher amplitudes during re-extinction for *non-met* allele carriers (t\[52\] = 2.42; *p* \< 0.05).

![A brief single conditioned stimulus (CS) display (i.e. memory reactivation) followed by extinction training within a reconsolidation window prevents spontaneous recovery in *met*-allele carriers of the brain derived neurotrophic factor (*BDNF*) genotype in humans. (A) Schematic representation of experimental procedure and chronology. (B) Mean differential skin conductance response (SCR; CS+ minus CS-) during fear acquisition (early phase), extinction (last four trials), and test for spontaneous recovery (first two trials compared to last four trials of extinction) were observed in the 20--26 hours for each experimental group (reminder and no-reminder). The *met*-allele group is shown with black bars and the *non-met* group with grey bars. Each bar show the ∆SCRs (CS+ minus CS-) and the error bars reflect the standard error of the mean. Both genetic groups (*met*-allele and *non-met* allele) showed equivalent fear acquisition and extinction. Statistical test scores comparing different phases for both groups (reminder and no-reminder) by allelic differences (*met* and *non-met* allele) are as follows: fear acquisition (early phase (trials 1--8) versus fear extinction (trials 13--16) over both allele groups in the reminder group (t~met~\[13\] = 3.16; *p* = 0.008; t~non-met~\[26\] = 4.87; *p* = 0.000) and no-reminder group (t~met~\[22\] = 6.78; *p* = 0.000; t~non-met~\[26\] = 7.96; *p* = 0.000). Further, spontaneous recovery was considered by using the ∆SCRs during the extinction (trials 13--16) and re-extinction (trials 1--2). Our *t*-test revealed spontaneous recovery in *met*-carriers for the reminder group (t~met~\[13\] = 3.34; *p* = 0.005) and no-reminder groups (t~met~\[22\] = -2.27; *p* = 0.03). The *non-met* allele carriers showed non-significant spontaneous recovery in the reminder (t~non-met~\[26\] = -0.66; *p* = 0.51) and no-reminder (t~non-met~\[26\] = -0.27; *p* = 0.79) groups. \**p* \< 0.05, \*\**p* \< 0.01.](ijnppy_pyv137_f0001){#F1}

To investigate the interaction effect of time x group x genotype, we calculated the differences between re-extinction and extinction (thereby eliminating the factor time), with negative values indicating a decrease from day 2 to day 3 in SCR for the contrast (CS+ minus CS- condition; see [Figure 2B](#F2){ref-type="fig"}).

![(A) Differential (conditioned stimulus \[CS+ minus CS-) skin conductance responses (SCRs) mean during extinction and re-extinction for both experimental groups and for the brain derived neurotrophic factor (*BDNF*) genotype. Error bars reflect standard error of the mean. (B) Differential (CS+ minus CS-) SCRs mean (re-extinction minus extinction) for both experimental groups and for *BDNF* genotype. Error bars reflect standard error of the mean. +*p* **\< 0.10, \*** *p* **\< 0.05, \*\*** *p* **\< 0.01.**](ijnppy_pyv137_f0002){#F2}

A comparison of the reminder to the no-reminder groups revealed a significantly larger decrease in ∆SCRs (CS+ minus CS-) for the *met*-allele carriers from extinction to re-extinction (t\[35\] = -3.3; *p* \< 0.003) in the reminder group. Additionally, we found that the *met*-allele carriers show a significantly larger decrease in the reminder group as compared to the *non-met* allele carriers (t\[39\] = -2.3; *p* \< 0.05). Furthermore, within the no-reminder group we found a significantly larger decrease in the *non-met* carriers as compared to the *met*-allele carriers (t\[35\] = 2.6; *p* \< 0.05).

Discussion {#s13}
==========

Blocking fear memory consolidation after reactivation moderates the return of fear ([@CIT0034]; [@CIT0046]), yet a significant number of studies have failed to target the reconsolidation mechanism and prevent fear from returning ([@CIT0010]; [@CIT0018]; [@CIT0023]; [@CIT0056]). [@CIT0046] developed the first drug-free paradigm that prevented fear memory from returning by using a reconsolidation mechanism in humans. Specifically, extinction training (i.e. repeated presentation of non-reinforced CSs) followed by memory reactivation has been shown to reduce the spontaneous recovery of fear the day after extinction training. It has been argued that the labile nature of memory after reactivation is necessary for memory maintenance or memory updating ([@CIT0003]). However, some studies failed to target the reconsolidation of memory in the human differential fear-conditioning paradigm. Therefore, our memory reactivation followed by extinction training is consistent with earlier investigations ([@CIT0010]; [@CIT0018]; [@CIT0023]) as it has been suggested that memory reactivation is not the sufficient condition for memory modification ([@CIT0047]; [@CIT0023]). The authors found evidence that a prediction error (i.e. the disparity between learned contingencies during fear acquisition and missing consequences during extinction training) is highly relevant for fear memory modification ([@CIT0048]). Discrepant findings with regard to fear reconsolidation led to the proposed hypothesis that allelic differences can moderate the fear reconsolidation mechanism. BDNF has a role in the stabilization of memory in an associative learning paradigm ([@CIT0007]), and thus may be a potential polymorphism for moderation of the fear reconsolidation mechanism. BDNF up- or down-regulation influences fear acquisition, extinction, and reacquisition. [@CIT0001a] showed in their study that the down-regulation of BDNF mRNA in the dentate gyrus of hippocampi in rats influences learning and memory. They also argued that reduction of BDNF mRNA in the dentate gyrus depends upon several factors, such as: (i) intensity, (ii) duration, and (iii) type of stress exposure. They explained that exposure to stressful cues, such as UCS or sensory cues associated with stressful situations, down-regulates the level of BDNF mRNA and reaches a normal level after 48 hours. Similarly, [@CIT0007] demonstrated in their study that BDNF protein signalling is a necessary prerequisite for the stabilization of memory at an interval of 12 hours post-learning. This suggests (i) dynamic regulation of BDNF protein in memory formation and (ii) that delayed regulation of BDNF is important in the persistence of memory. Hence, we hypothesized that BDNF is necessary for memory stabilization via a process of memory reconsolidation. Consistent with this prediction, our results showed an attenuation of differential SCRs reflecting memory reconsolidation as modulated by *BDNF* polymorphism. Furthermore, only *met*-carriers demonstrated reacquisition when presented with a reminder followed by extinction within the reconsolidation period, but not *BDNF val*66val allele homozygotes. These results suggest a hypostable pathological memory state in *met*-carriers, in accordance with previous studies ([@CIT0011]) showing memory dysfunctions in *BDNF met*-allele carriers. The current results are aligned with the consistent findings that the *met*-allele of the *BDNF* polymorphism is responsible for impairment in learning and memory ([@CIT0012]; [@CIT0050]; [@CIT0040]). Moreover, neuroimaging evidence indicates that the *met*-allele carriers have reduced hippocampal and prefrontal cortex volumes compared to the *non-met* allele carriers ([@CIT0041]).

Our results confirm those of a recent study ([@CIT0042]) showing that the intra-hippocampal infusion of BDNF antibodies immediately or 6h after extinction memory reactivation impaired the reconsolidation of extinction memory in rats. This recent study demonstrated the significance of BDNF in the persistence of extinction memory after reactivation. Along the same line, we also observed a lower persistence of fear memory after reactivation of the *BDNF val66met* genotype in *met*-allele carriers.

One of the questions that arises from our study is how allelic differences influence human fear reconsolidation. To our knowledge, only one study in humans has addressed this issue. [@CIT0002] reported the genetic modulation of fear memory persistence in humans selected for *5-HTTLPR* and *COMT* genotypes. Specifically, the *S*-carrier of *5-HTTLPR* and the *Val*-carrier of *COMT* displayed significantly higher SCRs for the reactivated-memory group outside the reconsolidation-window (i.e. 6 hours) compared to the group within the reconsolidation-window (i.e. 10min). The moderating effect of the *BDNF* polymorphism that we report here shares similar findings as previous investigation ([@CIT0002]).

Our results are also interesting in light of genetic predictors in post-traumatic stress disorder (PTSD). There has been considerable speculation that the *BDNF* genotype plays a significant role in the pathogenesis of PTSD. This speculation arises from the fact that the variance of PTSD is naturally heritable ([@CIT0015]). Recent preliminary evidence has affirmed the association of the *BDNF* genotype with PTSD symptoms ([@CIT0017]). The authors concluded that *met*-alleles showed behavioral resistance towards exposure therapy in PTSD compared to *val66val*. They also suggested the *met*-allele as a genetic predictor of exposure therapy in PTSD ([@CIT0017]). The present finding suggests that the coupling of memory reconsolidation and exposure therapy in healthy subjects with the *met*-allele may be responsible for diminishing spontaneous recovery, further accounting for the discrepant research findings in memory reconsolidation ([@CIT0010]; [@CIT0018]; [@CIT0023]; [@CIT0056]). It has been well esstablished that BDNF plays a critical role in the facilitation of neuronal differentiation and survival. Moreover, BDNF signalling is associated with abnormal fear memory and extinction ([@CIT0005]). A common single-neucleotide in the BDNF polymorphism (rs6265), which results in a valine to methionine substitution (val66met), leads to impaired fear memory ([@CIT0050]). Specifically, [@CIT0050] demonstrated the joint combination of heightened anxiety and impaired fear extinction in val66met compared to val66val allele carriers.

The clinical relevance of memory modification through targeting the reconsolidation of pathological memory has recently gained much attention ([@CIT0022]; [@CIT0030]). A recent study tested for the first time whether reactivation of fear memory prior to exposure therapy reduces relapse in a randomized clinical sample of arachnophobes ([@CIT0049]). However, both the control and experimental group benefited significantly from treatment and a return of fear was not observed for either group. Therefore, more research on the mechanisms of memory reconsolidation and the effects of fear reactivation on memory is necessary in order to enhance the effects of exposure therapy in the context of persistent pathological fears. Based on the results of our study, we would suggest taking inter-individual differences into account, for example with respect to the *BDNF* genotype. Additionally, several other factors have been shown to play a significant role in memory modulation. Factors such as memory strength, age of memory, and specificity of the CS are known as boundary conditions of memory ([@CIT0024]). For example, strong memories are susceptible to disruption and do not undergo reconsolidation ([@CIT0023]). Specifically, the rate of reinforcement level (i.e. CS-UCS associations) defines the strength of the memory, which directly affects memory reconsolidation after reactivation ([@CIT0039]).

We approached this study with the prior hypothesis that *BDNF* polymorphism partially prevents fear from returning by targeting a reconsolidation mechanism. However, the *BDNF val66met* polymorphism is unlikely to be the only genetic factor moderating the effects of reactivated fear memory on fear reconsolidation. It is likely that many other allelic differences are relevant in the persistence of fear memory in humans, as previously discussed. Although the current study demonstrated an effect of the *BDNF* polymorphism on fear memory reconsolidation and spontaneous recovery, some limitations of our finding must be taken into account. First, the small sample sizes of the groups may have affected the validity of the results. Second, we did not measure other threat-based physiological responses, such as the startle response, heart rate variability, and blood pressure. We also did not assess threat expectancies and contingency ratings for the CS-UCS association. The inclusion of other physiological and scaling data could have deepened our understanding of the threat expectancy and prediction error for different *BDNF* genotype groups. Finally, several undetected factors could also provide deeper insights into these measures, such as stress level and early undetected trauma. Despite these limitations, our study hints at the significant role of *BDNF* in fear memory reconsolidation after memory reactivation. In sum, our results show a moderation of a threat-based response after memory reactivation is significantly facilitated in *BDNF met*-carriers compared to *BDNF val66val* homozygotes.
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